Last reviewed · How we verify

NCT03525301

Short Course Radiation Therapy in Palliative Treatment of Brain Metastases

Status unknown NA Last updated 18 May 2018
What this trial tests

NA trial testing standard treatment in Brain Metastases in 108 participants. Status unknown.

Timeline
8 November 2017
Primary endpoint
8 November 2022
8 November 2023

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment108
Start date8 November 2017
Primary completion8 November 2022
Estimated completion8 November 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Brain Metastases or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic brain metastases from solid tumors

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of standard treatment

Trials testing the same drug.

Other recruiting trials for Brain Metastases

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03525301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing